Liposome-encapsulated Doxorubicin (Myocet) Plus Cyclophosphamide as First or Second Line Therapy for Older Patients With Metastatic Breast Cancer

Trial Profile

Liposome-encapsulated Doxorubicin (Myocet) Plus Cyclophosphamide as First or Second Line Therapy for Older Patients With Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 25 Sep 2015 Planned End Date changed from 1 Mar 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 25 Sep 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top